Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available
through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through
registered healthcare professionals.
Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting
continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK.
The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage.
"We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high
unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access
to and continuity of treatment for people living with obesity."
Day Lewis Pharmacy has enlisted Locate a Locum, a Belfast-based healthcare technology innovator, to deploy and manage a digital solution aimed at enhancing
locum staffing and management across its 267-pharmacy network.
"We sought a faster, user-friendly system for instant locum bookings, particularly for last-minute shifts," said Sam Patel, Executive Director at Day Lewis
Pharmacy. "This tool improves communication between potential locums and our coordinators, creating more opportunities to attract talent from across the country.
Our customers are our priority, and ensuring they have access to staff and advice when needed is our main focus."
Locate a Locum will implement a cloud-based digital solution across the Day Lewis Pharmacy estate, allowing locums to securely search, manage, request, and receive
payment for shifts, Day Lewis said in a statement. This platform enables locum staff to manage their work diaries, location preferences, and commitments, promoting
balanced work-life planning.
"The Locate a Locum platform allows for swift, complete payments to our locums and offers them instant booking, eliminating the need for shift confirmation wait
times," Patel added. "In a dynamic market with rising demand for pharmacy services, this platform is a game-changer, driving growth and unlocking potential."
A combination of factors, including the doctors' strike, medicine shortages, and funding scarcity, indicates that this upcoming winter could be the most
challenging period for both community pharmacies and the NHS, Community Pharmacy England has said.
In a September 4 blog post, CPE Chief Executive Janet Morrison emphasised that the relentless pressures show no signs of easing. "Pharmacy businesses, like
numerous other sectors, are grappling with the challenges of staying afloat in the current economic climate, compounded by the detrimental effects of historical
funding cuts."
"The doctors' strike, despite ongoing assurances from the Health Secretary that their pay deal is final, will inevitably exacerbate the demand for both primary
and secondary care, leading people to turn to their local pharmacies for assistance," she added. "This, in turn, will heighten the pressure on community pharmacies."
"Whatever the coming winter brings I am sure of two things: that community pharmacies are going to be more critical to the health of the population than ever
before, and that your representatives here will be fighting on all fronts to get you the help that you need."
The Health Select Committee Expert Panel has concluded in its report published on Tuesday (25 July) that the funding aspect in the community pharmacy sector
'requires improvement' based on the evidence received.
The Expert Panel reviewed nine Government commitments, seven of which were from the Community Pharmacy Contractual Framework.
It was found that available funding was not sufficient to keep pharmacies open, struggling financially with increased demand for dispensing, workforce pressures
and rising costs due to inflation. One of the other commitments requiring improvement covered a scheme intended to protect access to local physical NHS pharmaceutical
services in areas where there were fewer pharmacies.
Professor Dame Jane Dacre, Chair of the Expert Panel, said: "Pharmacy plays a key role in the delivery of care so it's disappointing that progress overall to
deliver on the Government's commitments was rated as 'requires improvement'.
Pharmanovia, a global pharmaceutical company has announced increased targets to divert 40 per cent of its air shipments to sea in 2023, and 75 per cent by the
end of 2028.
It has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report.
Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in
2022 - reducing Scope 3 upstream transport emissions by 18 per cent.
This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical
companies measured their entire Scope 3 emissions.
The new Sustainability Report reveals that the Scope 2 emissions decreasing by 13 per cent in 2022, due to lower direct electricity demand within the office space.
The company's packaging audit seeing a 52 per cent increase in the percentage of products packed with at least one fully recyclable component, up from 12% in 2021
to 64 per cent in 2022
Strong progress in an initiative which saw Pharmanovia set ESG goals all employees across its global offices as part of annual performance awards. Employees achieved
a 98 per cent completion rate of the compliance training, including ESG modules
Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called
Life Edit Therapeutics.
The Danish drugmaker's collaboration with Durham, North Carolina-based Life Edit Therapeutics - owned by ElevateBio, a cell and gene therapy company in Waltham - is
focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases.
At the heart of the tie-up is Life Edit's technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base - or
letter - into a different one without affecting other letters.
Single-letter mistakes, called point mutations, can give rise to genetic diseases.
Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general
practitioners even as the drug's market launch remains unclear.
The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults
with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme.
The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses
to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there.
British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals.
It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists".
The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.
The pharmacy inquiry will explore issues impacting different types of pharmacy, with a particular focus on community, primary care and hospital pharmacy
services.
It will also consider current challenges around funding, workforce and the digital infrastructure.
Planned developments within the profession will enable future pharmacists to be independent prescribers from day one of registration, giving them a greater role
within primary care teams.
Health and Social Care Committee Chair Steve Brine MP said: "It is clear that pharmacy has a central role to play in the future of the NHS. With a greater focus on
personalised and patient-centred healthcare, we will be asking what more must be done to make sure that the profession is in the best shape to meet demand.
"Better use of the pharmacy workforce would reduce pressures on general practice and hospitals. However, this will not happen without a planned workforce with the
funding, supervision and training to support it.
"At the end of the inquiry, the committee will be making recommendations to the government on what action needs to be taken to ensure the potential of pharmacy is
realised.
The Company Chemists' Association (CCA) has published a 'pharmacy paradox paper' which outlines how community pharmacy can match the ambition amidst the
workforce crisis.
The sector is experiencing a workforce crisis, exacerbated by NHS recruitment of community pharmacists into primary care networks. Pharmacies are also facing a
significant increase in demand on services.
CCA said, "A stretched and reduced pharmacy workforce is having to deliver more and more. This is unsustainable."
"Unless the tension between ambition and capacity is addressed, there is a risk that community pharmacies will not only not meet their potential, but the existing
offer could be compromised."
Therefore, the association has set out solutions to resolve the current paradox between ambition and reality.
Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document published
by Nuffield Trust and The King's Fund has revealed. It says community pharmacies in England must adapt to changing population needs amidst unprecedented health
and care challenges.
Commissioned by Community Pharmacy England, the report titled 'A Vision for Community Pharmacy', published on Sept. 19, is a result of almost a year of research
and extensive consultation with the sector and wider stakeholders, advocating for community pharmacy. The think tanks detail a shift in the community pharmacy
sector, highlighting how pharmacies can contribute to crucial policy objectives regarding population health, prevention, and the increasing demand in primary care.
"The health and care needs of the population are evolving, and pharmacies in England, like all components of the health and care system, must adjust to address
these changes," said Helen Buckingham, Director of Strategy at Nuffield Trust.
The Health Education England (HEE) has allocated £440,000 to help upskill pharmacists working in adult critical care across England.
UK Clinical Pharmacy Association (UKCPA) has confirmed with HEE that UKCPA critical care courses meet the criteria for this funding, for courses that complete before
31 March 2023.
"The funding is expected to exceed demand and so it is likely that bids for these UKCPA courses will be approved by HEE, as they meet the learning outcomes in the
new RPS/UKCPA/FICM specialist critical care curricula (in development)," said UKCPA.
What skills does a pharmacist need these days? You'd think it would be sufficient to have a good understanding of pharmacy and the ability to offer a great
patient service. Whilst this is true of course, the reality of the day to day role demands skills which most pharmacists have not been trained for as part of their
formal qualification.
At the very least, pharmacists find themselves responsible for running the pharmacy, managing people, managing processes and dealing with issues relating to customers,
suppliers, surgeries, regulators and stakeholders. Even the most junior pharmacists quickly find themselves being accountable for the financial performance of their
department and having to work within budgets or deliver on targets.
Remarkably, despite the apparent lack of any formal training in these areas, pharmacists have been able to adapt and meet the challenges of whatever their job has
thrown at them.
Many pharmacists go even further, bringing out their inner entrepreneurial spirit to set up their own business. There are now over 6,000 pharmacy businesses owned by
independent pharmacists, with this segment growing.
Whilst pharmacists have historically adapted to their environments and picked up the necessary business skills, the rapidly changing landscape of pharmacy will
require pharmacists to establish new skills to help ensure their businesses survive and thrive.
A winter NHS crisis is inevitable unless the government acts now to reverse the worrying decline in community pharmacies. Years of government underfunding could
see 3,000 pharmacies in England - around a third of the network - having no option but to shut their doors to patients in the next few years.
That figure is based on independent assessments from Ernst & Young and UCL/LSE healthcare professors: it is not scaremongering - it is the reality the country faces.
Fifty per cent of pharmacies are already in financial distress because government funding has been falling in real terms since 2019 and that figure is predicted to
rise to 75 per cent within the next two years.
The government needs to act now and invest in pharmacy or sleepwalk into a healthcare disaster as we have seen with access to dentistry care. Prescription volumes
have risen consistently year-on-year by roughly 2 per cent which means fewer pharmacies doing more work and under greater pressure than a decade ago. Ten years ago
around 11,200 pharmacies in England were dispensing roughly 79,000 prescriptions; nowadays around 11,500 are dispensing roughly 89,000 prescriptions.
The secretary of state recently asked pharmacy to do more to avoid a winter NHS crisis and at the same time said there will be no new money to pay for those
additional services. This at a time when the network is in decline with random unplanned pharmacy closures - 640 closures since 2016 - and pharmacy staff face huge
workload pressures as prescription demand is increasing year-on-year. The government's approach to pharmacy literally does not add up: the pharmacy contract is not
fit-for-purpose now let alone dealing with a NHS winter crisis.
Leaders from across the pharmacy sector and trade bodies dwelled on the challenges faced by the pharmacists at the Sigma Conference held on Sunday (2 October).
"If the cost of carrying out regulation is higher than the benefits, it's time for all the bodies to sit together and talk on what can be adjusted accordingly,"
said Salim Jetha, Chairman, Avicenna.
Jetha highlighted the challenges faced by the independent pharmacy and also raised the concern about the 'level playing field' for pharmacists compared to GPs. He
said: "GPs get paid for energy cost, premises cost, the staffing cost. We don't get paid for that. So don't be misled by saying we are being exactly the same. Yes,
on paper we are, but in reality we are not. I think also the rules of engagement are different."
He called for better collaboration with GPs, and urged PSNC and other trade bodies to ensure a level playing field.
Janet Morrison, CEO, Pharmaceutical Services Negotiating Committee(PSNC), warned that the pressure in the sector is building up to a 'breaking point'.
Community pharmacies in England will continue to receive the free protective equipment (PPE) as the Government's scheme has been extended for another year until
March 2024.
The Department of Health and Social Care (DHSC) has announced that it will continue to supply all categories of PPE, free of charge, for frontline health and social
care staff according to demand until the end of March 2024, or when stocks run out.
Last year, DHSC implemented a new and improved portal platform for eligible providers to access free COVID-19 related PPE supplies.
The Pharmaceutical Services Negotiating Commitee (PSNC) said: "Community pharmacy teams can continue to order PPE from the NHS PPE portal for free for as long as
stock is available."
The pharmacy bodies have expressed a deep concern over Lloyds Pharmacy's announcement on plans to close all pharmacy branches located in Sainsbury's before
the end of 2023.
Pharmaceutical Services Negotiating Committee (PSNC) Chief Executive Janet Morrison said: "This significant shrinkage by the second largest pharmacy chain is an
extremely worrying development and one of the clearest signals yet of just how much all community pharmacies are struggling to make ends meet. We know that many
are at breaking point."
She added: "We understand that LloydsPharmacy will be in touch directly with affected staff and patients at this difficult time. As these pharmacies close, other
pharmacies locally will be braced for even more pressures as they try to cope with increased demand."
"The announcement by LloydsPharmacy will be of concern to staff, patients, the public and the community pharmacy sector alike," Malcolm Harrison, Chief Executive
of the Company Chemists' Association (CCA).
Pharmacists, and other employees, working at pharmacies owned and operated by LloydsPharmacy in Sainsbury's have been told that the group of more than 200 pharmacies
will be closed this year as LloydsPharmacy will be ending their relationship with the supermarket chain.
Locate a Locum's analysis has found that there has been around 14 per cent rise in rate of locum pharmacists in a year.
The report said: "Post-covid locum pharmacist rates remain at an all-time high because of a variety of internal and external factors, including continued strong
local and regional demand for pharmacist services, which is more acute in some areas, and some persistent last-minute or unplanned booking activity among pharmacies."
The study is based on an analysis of more than 30,000 locum pharmacist shifts booked on the Locate a Locum platform between April 1 and June 30 this year and compared
with the same period in 2021.
"Locum pharmacy rates are a hot topic within the industry and this interest looks likely to continue, particularly given our latest analysis of rising prices and our
assessment that if current market conditions persist, they will continue to increase into 2023," said Locate a Locum founder and chief executive Jonathan Clarke.
The Department of Health and Social Care (DHSC) has announced that sufficient stock of Lipitor 10mg chewable tablets is now available to meet normal demand.
Therefore, the Serious Shortage Protocol, SSP032 Lipitor 10mg chewable tablets expired at 23.59pm on Friday (9 September).
"After this date, any prescriptions for Lipitor 10mg chewable tablets must be dispensed in accordance with the prescription, and the SSP032 will no longer be valid for use," said DHSC.
Businesses, including community pharmacies, that handle cash have been urged to prepare for the removal of £20 and £50 paper banknotes from circulation. The
paper notes of both denominations will no longer be legal tender from Friday 30 September.
Cash handling experts Volumatic reminded businesses to make sure that they deposit any paper notes at banks by this date, and ensure they would not be accepting any
further paper notes from customers from 1 October onwards.
"While businesses continue to face extra demands during the current cost-of living crisis, we've already seen evidence of an uplift in cash usage by consumers, who
are now using cash more to help them budget more effectively," Mike Severs, Sales and Marketing Director at Volumatic, said.
"With more consumers looking to spend their old paper notes before the end-of-September deadline, it's really important to remember to deposit any paper notes you
either already have within your business or receive throughout this month to your bank before the end of September."
The Hormone Replacement Therapy (HRT) Taskforce head Madelaine McTernan has returned to working full time as the director general of the Vaccine Taskforce for
autumn booster campaign preparation.
She has presented a few key recommendations to help ensure continued HRT supply to meet rising demand. "Improved access to data on prescriptions to more easily see
where there are shortfalls between HRT packs prescribed and HRT packs supplied by manufacturers," she suggested. "Taking lessons from the HRT supply chain work to
inform broader medicine supply work."
Madelaine said: "I am pleased to see the situation with HRT supply is improving across the country. I want to thank suppliers and manufacturers for their engagement
and positive action to tackle this serious issue.